„Drug repurposing“ und „orphan drug usage“

Neue Konzepte für die Gefäßchirurgie?

Drug repurposing and orphan drug usage

New concepts in vascular surgery?

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Hodos RA, Kidd BA, Shameer K et al (2016) In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8:186–210

    Article  Google Scholar 

  2. 2.

    Schüler J (2016) Die Biotechnologie-Industrie Ein Einführungs‑, Übersichtsund Nachschlagewerk. Springer Spektrum, Berlin Heidelberg

  3. 3.

    Knobloch J, Jungck D, Koch A (2017) The molecular mechanisms of thalidomide teratogenicity and implications for modern medicine. Curr Mol Med 17:108–117

    CAS  Article  Google Scholar 

  4. 4.

    Miro-Canturri A, Ayerbe-Algaba R, Smani Y (2019) Drug repurposing for the treatment of bacterial and fungal infections. Front Microbiol 10:41

    Article  Google Scholar 

  5. 5.

    Zheng W, Sun W, Simeonov A (2018) Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol 175:181–191

    CAS  Article  Google Scholar 

  6. 6.

    Anonymous (2018) Hamburg setzt auf neue Initiative für rationalen Antibiotikaeinsatz. Deutsches Ärzteblatt 19. April

  7. 7.

    Tulbah AS, Ong HX, Morgan L et al (2015) Dry powder formulation of simvastatin. Expert Opin Drug Deliv 12:857–868

    CAS  Article  Google Scholar 

  8. 8.

    Pallotta MT, Tascini G, Crispoldi R et al (2019) Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives. J Transl Med 17:238

    Article  Google Scholar 

  9. 9.

    Bissler JJ, Kingswood JC, Radzikowska E et al (2017) Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST‑2 study. PLoS ONE 12:e180939

    Article  Google Scholar 

  10. 10.

    Zanin M, Chorbev I, Stres B et al (2019) Community effort endorsing multiscale modelling, multiscale data science and multiscale computing for systems medicine. Brief Bioinformatics 20:1057–1062

    Article  Google Scholar 

  11. 11.

    Sun P, Guo J, Winnenburg R et al (2017) Drug repurposing by integrated literature mining and drug-gene-disease triangulation. Drug Discov Today 22:615–619

    CAS  Article  Google Scholar 

  12. 12.

    Liu Z, Fang H, Reagan K et al (2013) In silico drug repositioning: what we need to know. Drug Discov Today 18:110–115

    CAS  Article  Google Scholar 

  13. 13.

    Jin G, Wong ST (2014) Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19:637–644

    Article  Google Scholar 

  14. 14.

    Agrawal S, Vamadevan P, Mazibuko N et al (2019) A new method for ethical and efficient evidence generation for off-label medication use in oncology (A case study in Glioblastoma). Front Pharmacol 10:681

    Article  Google Scholar 

  15. 15.

    Burton M (2019) “Repurposing” off-patent drugs offers big hopes of new treatments. Economist. https://www.economist.com/international/2019/02/28/repurposing-off-patent-drugs-offers-big-hopes-of-new-treatments

  16. 16.

    Katsanos K, Spiliopoulos S, Kitrou P et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 7:e11245

    Article  Google Scholar 

  17. 17.

    Busch A, Chernogubova E, Jin H et al (2018) Four surgical modifications to the classic elastase perfusion aneurysm model enable haemodynamic alterations and extended elastase perfusion. Eur J Vasc Endovas Surg. https://doi.org/10.1016/j.ejvs.2018.03.018

    Article  Google Scholar 

  18. 18.

    Simon F, Oberhuber A (2016) Ischemia and reperfusion injury of the spinal cord: experimental strategies to examine postischemic paraplegia. Neural Regen Res 11:414–415

    Article  Google Scholar 

  19. 19.

    Eitenmuller I, Volger O, Kluge A et al (2006) The range of adaptation by collateral vessels after femoral artery occlusion. Circulation Research 99:656–662

    Article  Google Scholar 

  20. 20.

    Simon FH, Erhart P, Vcelar B et al (2016) Erythropoietin preconditioning improves clinical and histologic outcome in an acute spinal cord ischemia and reperfusion rabbit model. J Vasc Surg 64:1797–1804

    Article  Google Scholar 

  21. 21.

    Van Goor F, Straley KS, Cao D et al (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290:L1117–L1130

    Article  Google Scholar 

  22. 22.

    Donaldson SH, Pilewski JM, Griese M et al (2018) Tezacaftor/Ivacaftor in subjects with cystic fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. Am J Respir Crit Care Med 197:214–224

    CAS  Article  Google Scholar 

  23. 23.

    Hwang TC, Yeh JT, Zhang J et al (2018) Structural mechanisms of CFTR function and dysfunction. J Gen Physiol 150:539–570

    CAS  Article  Google Scholar 

  24. 24.

    Kuhnl A, Erk A, Trenner M et al (2017) Incidence, treatment and mortality in patients with abdominal aortic aneurysms. Dtsch Arztebl Int 114:391–398

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Trickett JP, Scott RA, Tilney HS (2002) Screening and management of asymptomatic popliteal aneurysms. J Med Screen 9:92–93

    CAS  Article  Google Scholar 

  26. 26.

    Jin H, Li DY, Chernogubova E et al (2018) Local delivery of miR-21 stabilizes fibrous caps in vulnerable atherosclerotic lesions. Mol Ther 26:1040–1055

    CAS  Article  Google Scholar 

  27. 27.

    Wang D, Deuse T, Stubbendorff M et al (2015) Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol 35:1945–1953

    CAS  Article  Google Scholar 

  28. 28.

    Golledge J, Moxon J, Pinchbeck J et al (2017) Association between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg 104:1486–1493

    CAS  Article  Google Scholar 

  29. 29.

    Fujimura N, Xiong J, Kettler EB et al (2016) Metformin treatment status and abdominal aortic aneurysm disease progression. J Vasc Surg 64:46–54e8

    Article  Google Scholar 

  30. 30.

    Villoutreix BO, Lagorce D, Labbe CM et al (2013) One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov Today 18:1081–1089

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to PD Dr. med. A. Busch.

Ethics declarations

Interessenkonflikt

M. Forstner, W. Eilenberg, F. Simon, M. Trenner, H.H. Eckstein, L. Maegdefessel und A. Busch geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Forstner, M., Eilenberg, W., Simon, F. et al. „Drug repurposing“ und „orphan drug usage“. Gefässchirurgie 24, 564–567 (2019). https://doi.org/10.1007/s00772-019-00573-8

Download citation